Neuropathic Pain Market By Drug class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Others), By Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Others), By Distribution channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2022-2032
The neuropathic pain market was valued at $7,717.4 million in 2022 and is estimated to reach $13,248.3 million by 2032, exhibiting a CAGR of 5.6% from 2023 to 2032. Neuropathic pain is caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain manifest in various ways, including stabbing, burning, tingling, or shooting sensations. It is often chronic and is challenging to treat. Various conditions that lead to neuropathic pain are diabetic neuropathy, postherpetic neuralgia (resulting from shingles), and trigeminal neuralgia.
Major factors that drive the growth of the global neuropathic pain market include advancements in drug of neuropathic pain; rise in number of research regarding neuropathic pain medication; and increase in number of patients suffering from neuropathic pain. Furthermore, surge in demand for medication of neuropathic pain, increase in awareness regarding diabetic neuropathy, upsurge in target population, and rise in number of clinical trials for the development of neuropathic pain boost the growth of neuropathic pain market. For instance, in October 2023, AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system announced that the company's presentation at the pain conference held by the Swedish Pain Society is now available in its entirety on the company's website. The presentation contains clinical data from the phase II study with the company's leading drug candidate in pain, ACD440, which is being developed for the treatment of peripheral neuropathic pain.
However, the side effects of neuropathic pain medicines and high cost of branded medications are expected to restrict the growth of neuropathic pain market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future.
The neuropathic pain market is segmented on the basis of drug class, indication, distribution channel, and region. On the basis of drug class, the market is divided into antidepressants, anticonvulsant, opioids, capsaicin, and others. The antidepressants segment is further categorized into tricyclic antidepressants and serotonin–noradrenaline reuptake inhibitors (SNRI). On the basis of indication, the market is classified into diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others. On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Abbott Laboratories, Collegium Pharmaceutical, Inc., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grünenthal, Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted agreement, acquisition, clinical trial, and product approval as key developmental strategies to improve the product portfolio of the neuropathic pain market.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuropathic pain market analysis from 2022 to 2032 to identify the prevailing neuropathic pain market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neuropathic pain market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neuropathic pain market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug class
Antidepressants
Type
Tricyclic Antidepressants
Serotonin–Noradrenaline Reuptake Inhibitors (SNRI)
Anticonvulsant
Opioids
Capsaicin
Others
By Indication
Diabetic Neuropathy
Spinal Stenosis
Chemotherapy-Induced Peripheral Neuropathy
Others
By Distribution channel
Hospital Pharmacies
Drugs Stores and Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
Teva Pharmaceuticals
Novartis AG
Eli Lilly and Company.
Mallinckrodt Pharmaceuticals
Collegium Pharmaceutical Inc
Sun Pharmaceutical Industries Ltd.
Abbott Laboratories
Glenmark Pharmaceuticals Limited
Grunenthal GmbH.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in cases of neuropathic pain
- 3.4.1.2. Rise in prevalence of chronic diseases
- 3.4.1.3. Rise in geriatric population
- 3.4.2. Restraints
- 3.4.2.1. Side effects of neuropathic pain medicine
- 3.4.3. Opportunities
- 3.4.3.1. Rise in number of drugs in pipeline
- CHAPTER 4: NEUROPATHIC PAIN MARKET, BY DRUG CLASS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Antidepressants
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Antidepressants Neuropathic Pain Market by Type
- 4.3. Anticonvulsant
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Opioids
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Capsaicin
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- CHAPTER 5: NEUROPATHIC PAIN MARKET, BY INDICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Diabetic Neuropathy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Spinal Stenosis
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Chemotherapy-Induced Peripheral Neuropathy
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- CHAPTER 6: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drugs Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: NEUROPATHIC PAIN MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Drug class
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Drug class
- 7.2.5.1.2. Market size and forecast, by Indication
- 7.2.5.1.3. Market size and forecast, by Distribution channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Drug class
- 7.2.5.2.2. Market size and forecast, by Indication
- 7.2.5.2.3. Market size and forecast, by Distribution channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Drug class
- 7.2.5.3.2. Market size and forecast, by Indication
- 7.2.5.3.3. Market size and forecast, by Distribution channel
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Drug class
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Drug class
- 7.3.5.1.2. Market size and forecast, by Indication
- 7.3.5.1.3. Market size and forecast, by Distribution channel
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Drug class
- 7.3.5.2.2. Market size and forecast, by Indication
- 7.3.5.2.3. Market size and forecast, by Distribution channel
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Drug class
- 7.3.5.3.2. Market size and forecast, by Indication
- 7.3.5.3.3. Market size and forecast, by Distribution channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Drug class
- 7.3.5.4.2. Market size and forecast, by Indication
- 7.3.5.4.3. Market size and forecast, by Distribution channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Drug class
- 7.3.5.5.2. Market size and forecast, by Indication
- 7.3.5.5.3. Market size and forecast, by Distribution channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Drug class
- 7.3.5.6.2. Market size and forecast, by Indication
- 7.3.5.6.3. Market size and forecast, by Distribution channel
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Drug class
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Drug class
- 7.4.5.1.2. Market size and forecast, by Indication
- 7.4.5.1.3. Market size and forecast, by Distribution channel
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Drug class
- 7.4.5.2.2. Market size and forecast, by Indication
- 7.4.5.2.3. Market size and forecast, by Distribution channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Market size and forecast, by Drug class
- 7.4.5.3.2. Market size and forecast, by Indication
- 7.4.5.3.3. Market size and forecast, by Distribution channel
- 7.4.5.4. India
- 7.4.5.4.1. Market size and forecast, by Drug class
- 7.4.5.4.2. Market size and forecast, by Indication
- 7.4.5.4.3. Market size and forecast, by Distribution channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Drug class
- 7.4.5.5.2. Market size and forecast, by Indication
- 7.4.5.5.3. Market size and forecast, by Distribution channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Drug class
- 7.4.5.6.2. Market size and forecast, by Indication
- 7.4.5.6.3. Market size and forecast, by Distribution channel
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Drug class
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Drug class
- 7.5.5.1.2. Market size and forecast, by Indication
- 7.5.5.1.3. Market size and forecast, by Distribution channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Drug class
- 7.5.5.2.2. Market size and forecast, by Indication
- 7.5.5.2.3. Market size and forecast, by Distribution channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Drug class
- 7.5.5.3.2. Market size and forecast, by Indication
- 7.5.5.3.3. Market size and forecast, by Distribution channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Drug class
- 7.5.5.4.2. Market size and forecast, by Indication
- 7.5.5.4.3. Market size and forecast, by Distribution channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Teva Pharmaceuticals
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Glenmark Pharmaceuticals Limited
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.5. Mallinckrodt Pharmaceuticals
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Eli Lilly and Company.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Grunenthal GmbH.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Collegium Pharmaceutical Inc
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Sun Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Abbott Laboratories
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 02. NEUROPATHIC PAIN MARKET FOR ANTIDEPRESSANTS, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. GLOBAL ANTIDEPRESSANTS NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 04. NEUROPATHIC PAIN MARKET FOR ANTICONVULSANT, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. NEUROPATHIC PAIN MARKET FOR OPIOIDS, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. NEUROPATHIC PAIN MARKET FOR CAPSAICIN, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. NEUROPATHIC PAIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 09. NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. NEUROPATHIC PAIN MARKET FOR SPINAL STENOSIS, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. NEUROPATHIC PAIN MARKET FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. NEUROPATHIC PAIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 14. NEUROPATHIC PAIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. NEUROPATHIC PAIN MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 16. NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 17. NEUROPATHIC PAIN MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 18. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 19. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 20. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 21. NORTH AMERICA NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 22. U.S. NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 23. U.S. NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 24. U.S. NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 25. CANADA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 26. CANADA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 27. CANADA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 28. MEXICO NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 29. MEXICO NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 30. MEXICO NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 31. EUROPE NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 32. EUROPE NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 33. EUROPE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 34. EUROPE NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 35. GERMANY NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 36. GERMANY NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 37. GERMANY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 38. FRANCE NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 39. FRANCE NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 40. FRANCE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 41. UK NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 42. UK NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 43. UK NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 44. ITALY NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 45. ITALY NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 46. ITALY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 47. SPAIN NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 48. SPAIN NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 49. SPAIN NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 50. REST OF EUROPE NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 51. REST OF EUROPE NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 52. REST OF EUROPE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 53. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 54. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 55. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 56. ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 57. JAPAN NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 58. JAPAN NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 59. JAPAN NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 60. CHINA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 61. CHINA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 62. CHINA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 63. AUSTRALIA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 64. AUSTRALIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 65. AUSTRALIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 66. INDIA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 67. INDIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 68. INDIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 69. SOUTH KOREA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 70. SOUTH KOREA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 71. SOUTH KOREA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 72. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 73. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 74. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 75. LAMEA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 76. LAMEA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 77. LAMEA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 78. LAMEA NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 79. BRAZIL NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 80. BRAZIL NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 81. BRAZIL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 82. SAUDI ARABIA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 83. SAUDI ARABIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 84. SAUDI ARABIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 85. SOUTH AFRICA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 86. SOUTH AFRICA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 87. SOUTH AFRICA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 88. REST OF LAMEA NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 89. REST OF LAMEA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 90. REST OF LAMEA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 91. PFIZER INC.: KEY EXECUTIVES
- TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 95. TEVA PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 96. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 97. TEVA PHARMACEUTICALS: PRODUCT SEGMENTS
- TABLE 98. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 99. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
- TABLE 100. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
- TABLE 101. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
- TABLE 102. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
- TABLE 103. NOVARTIS AG: KEY EXECUTIVES
- TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 107. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 108. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 109. MALLINCKRODT PHARMACEUTICALS: PRODUCT SEGMENTS
- TABLE 110. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 111. ELI LILLY AND COMPANY.: KEY EXECUTIVES
- TABLE 112. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
- TABLE 113. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
- TABLE 114. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
- TABLE 115. ELI LILLY AND COMPANY.: KEY STRATERGIES
- TABLE 116. GRUNENTHAL GMBH.: KEY EXECUTIVES
- TABLE 117. GRUNENTHAL GMBH.: COMPANY SNAPSHOT
- TABLE 118. GRUNENTHAL GMBH.: PRODUCT SEGMENTS
- TABLE 119. GRUNENTHAL GMBH.: PRODUCT PORTFOLIO
- TABLE 120. GRUNENTHAL GMBH.: KEY STRATERGIES
- TABLE 121. COLLEGIUM PHARMACEUTICAL INC: KEY EXECUTIVES
- TABLE 122. COLLEGIUM PHARMACEUTICAL INC: COMPANY SNAPSHOT
- TABLE 123. COLLEGIUM PHARMACEUTICAL INC: PRODUCT SEGMENTS
- TABLE 124. COLLEGIUM PHARMACEUTICAL INC: PRODUCT PORTFOLIO
- TABLE 125. COLLEGIUM PHARMACEUTICAL INC: KEY STRATERGIES
- TABLE 126. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 127. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 130. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 131. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 132. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 133. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. NEUROPATHIC PAIN MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF NEUROPATHIC PAIN MARKET,2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN NEUROPATHIC PAIN MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN NEUROPATHIC PAIN MARKET (2022-2032)
- FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 06. LOW THREAT OF NEW ENTRANTS
- FIGURE 07. LOW THREAT OF SUBSTITUTES
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. LOW BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL NEUROPATHIC PAIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR ANTICONVULSANT, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR OPIOIDS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR CAPSAICIN, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. NEUROPATHIC PAIN MARKET, BY INDICATION, 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR SPINAL STENOSIS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 25. COMPARATIVE SHARE ANALYSIS OF NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 26. NEUROPATHIC PAIN MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 27. U.S. NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 28. CANADA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 29. MEXICO NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 30. GERMANY NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 31. FRANCE NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 32. UK NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 33. ITALY NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 34. SPAIN NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 35. REST OF EUROPE NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 36. JAPAN NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 37. CHINA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 38. AUSTRALIA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 39. INDIA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SOUTH KOREA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 41. REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 42. BRAZIL NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 43. SAUDI ARABIA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 44. SOUTH AFRICA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 45. REST OF LAMEA NEUROPATHIC PAIN MARKET, 2022-2032 ($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
- FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50. COMPETITIVE DASHBOARD
- FIGURE 51. COMPETITIVE HEATMAP: NEUROPATHIC PAIN MARKET
- FIGURE 52. TOP PLAYER POSITIONING, 2022
- FIGURE 53. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 55. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 56. TEVA PHARMACEUTICALS: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 57. TEVA PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 58. TEVA PHARMACEUTICALS: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 59. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 60. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 61. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 62. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 63. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 64. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
- FIGURE 65. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 66. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 67. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 68. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 69. GRUNENTHAL GMBH.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 70. GRUNENTHAL GMBH.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 71. GRUNENTHAL GMBH.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 72. COLLEGIUM PHARMACEUTICAL INC: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 73. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 74. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 75. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
- FIGURE 76. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 77. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook